↓ Skip to main content

Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: Pooled results from three countries

Overview of attention for article published in Breast Cancer Research, June 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (76th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (63rd percentile)

Mentioned by

twitter
6 tweeters
googleplus
1 Google+ user

Citations

dimensions_citation
60 Dimensions

Readers on

mendeley
75 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: Pooled results from three countries
Published in
Breast Cancer Research, June 2012
DOI 10.1186/bcr3206
Pubmed ID
Authors

Michael E Jones, Flora E van Leeuwen, Wilhelmina E Hoogendoorn, Marian JE Mourits, Harry Hollema, Hester van Boven, Michael F Press, Leslie Bernstein, Anthony J Swerdlow

Abstract

Tamoxifen is an effective treatment for breast cancer but an undesirable side-effect is an increased risk of endometrial cancer, particularly rare tumor types associated with poor prognosis. We investigated whether tamoxifen therapy increases mortality among breast cancer patients subsequently diagnosed with endometrial cancer.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 75 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Egypt 2 3%
United Kingdom 1 1%
Unknown 72 96%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 15 20%
Researcher 10 13%
Student > Ph. D. Student 9 12%
Student > Master 9 12%
Student > Postgraduate 5 7%
Other 16 21%
Unknown 11 15%
Readers by discipline Count As %
Medicine and Dentistry 32 43%
Agricultural and Biological Sciences 8 11%
Pharmacology, Toxicology and Pharmaceutical Science 5 7%
Biochemistry, Genetics and Molecular Biology 5 7%
Nursing and Health Professions 2 3%
Other 8 11%
Unknown 15 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 February 2022.
All research outputs
#5,330,589
of 21,842,516 outputs
Outputs from Breast Cancer Research
#657
of 1,855 outputs
Outputs of similar age
#33,995
of 143,684 outputs
Outputs of similar age from Breast Cancer Research
#17
of 47 outputs
Altmetric has tracked 21,842,516 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,855 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.8. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 143,684 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.